PK = Deltagen Inc. PRXL = Parexel International Corp. Pvt1 = Quintiles Transnational Corp. (privately held) Industry = Biotechnology As of 2005 Source: Yahoo! Finance, April 29, 2007. Figure 1. Financial Performance: Charles River Laboratories vs. Deltagen Inc. And Parexel International Corp. - January 2002 to date. Source: Yahoo! Finance, April 29, 2007. Operating income for 2006 was reported by the company to be $188.2 million compared to $184.7 million for 2005 and its operating margin for 2006

This situation illustrates the difficulties in navigating an uncertain regulatory environment. 3. It is reasonable that the WHO guidelines are used as the framework for U.S. policy. The U.S. system, however, is unique in certain ways. You alluded to the need to encourage innovation. The balance between innovation and cost control is different in the U.S. than in Europe, so I think that is why U.S. policy will look slightly

Other avenues include television, newspapers and magazines, radio, web pages, and people to people exchange. Effective communication should be built on an understanding of the nature of consumer concerns. Information on biotechnology modifications should include the reasons for modification, degree of regulatory oversight, methods and extent of safety verification, and impact of modification on consumer safety and the environment." (Bruhn, nd) According to a report from the Food Policy

Corn pollen had a high mortality rate (44% in 4 days) compared to those fed on and regular corn pollen showing no mortality. [Frontline/Nova] The allergenic potential of the transgenes that are used in GM products is a frightening problem. A noticeable case is that of Pioneer Hi-Bred INC, the international seed company that produced a genetically modified and enriched Soybean using the Brazilian nut gene. Fortunately, before the product

1). Prior to market introduction of a GMO for commercial use in any part of the EU, notification must be sent to the competent member state authority where the GMO will be released (Council Directive 90/220/EEC, art. 11 (1)). Notification must include a risk assessment with information necessary for evaluating the foreseeable risks posed by the GMO to human health or the environment, to which the competent authority will

Translating Biomedical Innovation / Mental Health and well being Managing Ideas: Commercialization Strategies for Biotechnology This article by Joshua and Scott Focuses on the commercialization aspect of biotechnology and stresses how important it is for innovators in the new and fast developing field of biotechnology to effectively forge collaboration with existing pharmaceutical market leaders in order to successfully create a new and strong value proposition for the healthcare sector. Biotech firms have